Addition of MR imaging features and genetic biomarkers strengthens glioblastoma survival prediction in TCGA patients

Journal of Neuroradiology

Volumn 42, Issue 4, 2015, Pages 212-221

  Nicolasjilwan, Manal ^a   Hu, Ying ^b   Yan, Chunhua ^b   Meerzaman, Daoud ^b   Holder, Chad A ^c   Gutman, David ^c   Jain, Rajan ^d   Colen, Rivka ^e   Rubin, Daniel L ^f   Zinn, Pascal O ^e   Hwang, Scott N ^g   Raghavan, Prashant ^a   Hammoud, Dima A ^h   Scarpace, Lisa M ^d   Mikkelsen, Tom ^d   Chen, James ⁱ   Gevaert, Olivier ^j   Buetow, Kenneth ^k   Freymann, John ^l   Kirby, Justin ^l   Flanders, Adam E ^m   Wintermark, Max ^a,n   more..

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Departments of Radiation Oncology and Neurosurgery   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f STANFORD UNIVERSITY   (United States)

^g ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k ARIZONA STATE UNIVERSITY   (United States)

^l SAIC FREDERICK INC   (United States)

^m THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

ⁿ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

more..

Author keywords

Genetics; Glioblastoma; Magnetic resonance imaging; Prognosis; Survival

Indexed keywords

ACCURACY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CONTRAST ENHANCEMENT; COPY NUMBER VARIATION; EGFR GENE; ERBB2 GENE; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC MARKER; GENOME; GENOMICS; GLIOBLASTOMA; HUMAN; IDH1 GENE; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NF1 GENE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE H RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PDGFRA GENE; PIK3CA GENE; PIK3R1 GENE; PREDICTION; PTEN GENE; RB1 GENE; SCORING SYSTEM; TUMOR SUPPRESSOR GENE; BRAIN NEOPLASMS; EPIDEMIOLOGY; GENETIC PREDISPOSITION; GENETICS; MORTALITY; PREVALENCE; PROCEDURES; REPRODUCIBILITY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

GENETIC MARKER; TUMOR MARKER;

BIOMARKERS, TUMOR; BRAIN NEOPLASMS; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PREVALENCE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 84937640437     PISSN: 01509861     EISSN: 17730406     Source Type: Journal    
DOI: 10.1016/j.neurad.2014.02.006     Document Type: Article

References (29)

1. Verger E., Valduvieco I., Caral L., et al. Does gender matter in glioblastoma?. Clin Transl Oncol 2011, 13:737-741.
2. Marina O., Suh J.H., Reddy C.A., et al. Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Clinical article. J Neurosurg 2011, 115:220-229.
3. Allahdini F., Amirjamshidi A., Reza-Zarei M., et al. Evaluating the prognostic factors effective on the outcome of patients with glioblastoma multiformis: does maximal resection of the tumor lengthen the median survival?. World Neurosurg 2010, 73:128-134. [discussion e16].
4. Barker F.G., Chang S.M., Larson D.A., et al. Age and radiation response in glioblastoma multiforme. Neurosurgery 2001, 49:1288-1297. [discussion 1297-8].
5. Chaichana K., Parker S., Olivi A., et al. A proposed classification system that projects outcomes based on preoperative variables for adult patients with glioblastoma multiforme. J Neurosurg 2010, 112:997-1004.
6. Murakami R., Sugahara T., Nakamura H., et al. Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging. Radiology 2007, 243:493-499.
7. Pope W.B., Sayre J., Perlina A., et al. MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 2005, 26:2466-2474.
8. Li X., Jin H., Lu Y., et al. Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas. NMR Biomed 2004, 17:10-20.
9. Steltzer K.J., Sauve K.I., Spence A.M., et al. Corpus callosum involvement as a prognostic factor for patients with high-grade astrocytoma. Int J Radiat Oncol Biol Phys 1997, 38:27-30.
10. Gutman D.A., Cooper L.A., Hwang S.N., et al. MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology 2013, 267:560-569.
11. Zolal A., Hejcl A., Malucelli A., et al. Distant white-matter diffusion changes caused by tumor growth. J Neuroradiol 2013, 40:71-80.
12. Verhaak R.G., Hoadley K.A., Purdom E., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
13. Serao N.V., Delfino K.R., Southey B.R., et al. Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival. BMC Med Genomics 2011, 4:49.
14. Jung C.S., Unterberg A.W., Hartmann C. Diagnostic markers for glioblastoma. Histol Histopathol 2011, 26:1327-1341.
15. Parsa A.T. Functional validation confirms genomic phenotypes of glioblastoma with implications for targeted therapy. World Neurosurg 2011, 75:573-574.
16. Brennan C. Genomic profiles of glioma. Curr Neurol Neurosci Rep 2011, 11:291-297.
17. Zinn P.O., Sathyan P., Mahajan B., et al. A novel volume-age-KPS (VAK) glioblastoma classification identifies a prognostic cognate microRNA-gene signature. PLoS One 2012, 7:e41522.
18. Phillips H.S., Kharbanda S., Chen R., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9:157-173.
19. Agarwal A., Kumar S., Narang J., et al. Morphologic MRI features, diffusion tensor imaging and radiation dosimetric analysis to differentiate pseudo-progression from early tumor progression. J Neurooncol 2013, 112:413-420.
20. Akaike H. A Bayesian analysis of the minimum AIC procedure. Selected Papers of Hirotugu Akaike 1998, 275-280. Springer, New York. E. Parzen, K. Tanabe, G. Kitagawa (Eds.).
21. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc 1995, 57:289-300.
22. Johnson D.R., O'Neill B.P. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 2012, 107:359-364.
23. Martino A., Krainik A., Pasteris C., et al. Neurological imaging of brain damages after radiotherapy and/or chimiotherapy. J Neuroradiol 2014, 41:52-70.
24. Bauchet L., Mathieu-Daude H., Fabbro-Peray P., et al. Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro Oncol 2010, 12:725-735.
25. Shirai K., Suzuki Y., Okamoto M., et al. Influence of histological subtype on survival after combined therapy of surgery and radiation in WHO grade 3 glioma. J Radiat Res 2010, 51:589-594.
26. Robertson T., Koszyca B., Gonzales M. Overview and recent advances in neuropathology. Part 1: central nervous system tumours. Pathology 2011, 43:88-92.
27. Jain R., Poisson L., Narang J., et al. Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. Radiology 2012, 267:212-220.
28. Moliterno J.A., Patel T.R., Piepmeier J.M. Neurosurgical approach. Cancer J 2012, 18:20-25.
29. Kondo T. Mouse induced glioma-initiating cell models and therapeutic targets. Anticancer Agents Med Chem 2010, 10:471-480.